Skip to main content
. Author manuscript; available in PMC: 2016 May 15.
Published in final edited form as: ACS Chem Biol. 2015 Feb 20;10(5):1217–1226. doi: 10.1021/cb500843r

Figure 3.

Figure 3

Inhibition of SLS production. (A) Hemolytic activity of SLS extracts from S. pyogenes treated with HIV protease inhibitors. Tipranavir is shown separated by a dashed line due to significant growth effects during treatment (Figure S5). Asterisks indicate a P-value < 0.01 relative to the DMSO control. (B) The structure of nelfinavir (1). (C) The proteolytic effect of S. pyogenes membranes treated with nelfinavir on MBP-SagA, relative to a DMSO-treated control.